Biopharma · FDA Approvals · Stock

CLDX Celldex

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single…

Assets on file: barzolvolimab

Start live analysis of CLDX Run 8-agent AI analysis Stock overview All sector events →

Catalyst calendar

Dated catalysts for CLDX, including recently decided ones.

October 2026

Quarter only

~ Quarter only

CLDXCelldex

Celldex presents long-term barzolvolimab angioedema data at EAACI 2026

Trial readoutCompany press releaseQuarter only

Oct 2026

~ Oct 2026

CLDXCelldex

barzolvolimab: Phase 3 trial NCT06455202 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Oct 2026

~ Oct 2026

CLDXCelldex

barzolvolimab: Phase 3 trial NCT06445023 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

June 2028

Jun 2028

~ Jun 2028

CLDXCelldex

barzolvolimab: Phase 3 trial NCT07266402 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

September 2028

Sep 2028

~ Sep 2028

CLDXCelldex

barzolvolimab: Phase 3 trial NCT07256392 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for CLDX, newest first.

Instant stream — events appear as soon as they are filed.

Notable

Jun 14, 2026

02:21 PM

CLDXCelldex

Celldex presents long-term barzolvolimab angioedema data at EAACI 2026

Phase 2 data presented at EAACI show sustained off-treatment angioedema control (up to 64% angioedema-free at Week 76). The company reiterated that two Phase 3 CSU trials are fully enrolled and topline data are expected in Q4 2026, supporting a planned BLA submission in 2027.

Conference presentationCompany press release